Provided by Tiger Trade Technology Pte. Ltd.

Travere Therapeutics, Inc.

57.15
-1.7300-2.94%
Volume:1.02M
Turnover:58.32M
Market Cap:5.39B
PE:-119.95
High:59.56
Open:58.64
Low:56.23
Close:58.88
52wk High:68.73
52wk Low:22.59
Shares:94.26M
Float Shares:92.77M
Volume Ratio:0.80
T/O Rate:1.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4764
EPS(LYR):-0.2864
ROE:-236.35%
ROA:-3.73%
PB:219.68
PE(LYR):-199.58

Loading ...

Ardelyx Says Q2 Product Revenue at Record High but Ibsrela Revenue Below Expectations

Reuters
·
Aug 07

Wedbush Sticks to Their Buy Rating for Travere Therapeutics (TVTX)

TIPRANKS
·
Aug 06

Travere Therapeutics, Inc. : Wedbush Raises Target Price to $75 from $61

THOMSON REUTERS
·
Aug 06

Regulatory Uncertainty Threatens Travere Therapeutics’ Cross-Border Deals and Partnerships

TIPRANKS
·
Aug 06

Travere Therapeutics to Present at Canaccord Genuity Growth Conference

Reuters
·
Aug 06

Akebia Q2 Revenue Falls on Lower Auryxia Sales

Reuters
·
Aug 06

Sarepta Q2 Results Beat Expectations Despite Lower Sales Stemming from Elevidys Relabel, Unmet Roche Milestone

Reuters
·
Aug 06

Mirum Pharmaceuticals Q2 Sales Rise, Lifts Outlook

Reuters
·
Aug 06

Does FILSPARI-Driven Revenue Growth And Wider Losses Change The Bull Case For Travere Therapeutics (TVTX)?

Simply Wall St.
·
Aug 06

United Therapeutics Q2 Revenue Misses Estimates on Ebulized Tyvaso Weakness

Reuters
·
Aug 05

Travere Therapeutics, Inc. : Jefferies Raises Target Price to $64 from $54

THOMSON REUTERS
·
Aug 05

Travere Therapeutics (TVTX) Stock Rallies Over 13% After Hours: Here's What Is Going On

Benzinga Earnings
·
Aug 05

Travere Therapeutics, Inc. : TD Cowen Raises Target Price to $75 from $60

THOMSON REUTERS
·
Aug 05

Travere Therapeutics, Inc. : Guggenheim Raises Target Price to $75 from $65

THOMSON REUTERS
·
Aug 05

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 05

Stock Track | Travere Therapeutics Soars 7.18% as Q2 Results Beat Estimates on Robust FILSPARI Sales Growth

Stock Track
·
Aug 05

Travere Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

Stock Track | Travere Therapeutics Soars 11.3% After-Hours on Strong FILSPARI Sales Growth and Q2 Product Revenue Beat

Stock Track
·
Aug 05

Travere Therapeutics Q2 Product Sales Rise on Filspari Demand

Reuters
·
Aug 05

Travere Q2 FY26 Net Loss Widens to $34.8 Million; Filspari Net Sales Rise 96% Year-over-Year to $141.1 Million

Reuters
·
Aug 05